A prospective, multi-center, phase IV clinical study to assess the safety and clinical outcome of acalabrutinib in Indian adult patients with chronic lymphocytic leukemia/small lymphocytic lymphoma or relapsed/refractory mantle cell lymphoma

Pankaj Malhotra, Dinesh Bhurani, Manju Sengar, Nitin Sood, Arijit Nag, Anil Aribandi, Biju George, Hari Menon, Jina Bhattacharyya, Mallikarjun Kalashetty, Narendra Agrawal, Neeraj Sidharthan, Rayaz Ahmed, Sandip Shah, Saurav Bhave, Sharat Damodar

Open source

DOI: 10.3389/fonc.2026.1822178
Published: 2026-09-10
Container: Frontiers in Oncology
Publisher: Frontiers Media SA
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.3389/fonc.2026.1822178,
  title = {A prospective, multi-center, phase IV clinical study to assess the safety and clinical outcome of acalabrutinib in Indian adult patients with chronic lymphocytic leukemia/small lymphocytic lymphoma or relapsed/refractory mantle cell lymphoma},
  author = {Pankaj Malhotra and Dinesh Bhurani and Manju Sengar and Nitin Sood and Arijit Nag and Anil Aribandi and Biju George and Hari Menon and Jina Bhattacharyya and Mallikarjun Kalashetty and Narendra Agrawal and Neeraj Sidharthan and Rayaz Ahmed and Sandip Shah and Saurav Bhave and Sharat Damodar},
  year = {2026},
  journal = {Frontiers in Oncology},
  doi = {10.3389/fonc.2026.1822178},
  url = {https://doi.org/10.3389/fonc.2026.1822178}
}

RIS

TY  - JOUR
TI  - A prospective, multi-center, phase IV clinical study to assess the safety and clinical outcome of acalabrutinib in Indian adult patients with chronic lymphocytic leukemia/small lymphocytic lymphoma or relapsed/refractory mantle cell lymphoma
AU  - Pankaj Malhotra
AU  - Dinesh Bhurani
AU  - Manju Sengar
AU  - Nitin Sood
AU  - Arijit Nag
AU  - Anil Aribandi
AU  - Biju George
AU  - Hari Menon
AU  - Jina Bhattacharyya
AU  - Mallikarjun Kalashetty
AU  - Narendra Agrawal
AU  - Neeraj Sidharthan
AU  - Rayaz Ahmed
AU  - Sandip Shah
AU  - Saurav Bhave
AU  - Sharat Damodar
PY  - 2026
JO  - Frontiers in Oncology
DO  - 10.3389/fonc.2026.1822178
UR  - https://doi.org/10.3389/fonc.2026.1822178
ER  -

APA

Malhotra, P., Bhurani, D., Sengar, M., Sood, N., Nag, A., Aribandi, A., George, B., Menon, H., Bhattacharyya, J., Kalashetty, M., Agrawal, N., Sidharthan, N., Ahmed, R., Shah, S., Bhave, S., & Damodar, S. (2026). A prospective, multi-center, phase IV clinical study to assess the safety and clinical outcome of acalabrutinib in Indian adult patients with chronic lymphocytic leukemia/small lymphocytic lymphoma or relapsed/refractory mantle cell lymphoma. Frontiers in Oncology. https://doi.org/10.3389/fonc.2026.1822178

Source records

crossref · retrieved 2026-09-25T23:22:20.898Z